HNSA — Hansa Biopharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK2.90bn
- SEK3.46bn
- SEK171.32m
Annual income statement for Hansa Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.1 | 33.9 | 155 | 134 | 171 |
| Cost of Revenue | |||||
| Gross Profit | 5.1 | 18.5 | 116 | 71 | 87.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 429 | 581 | 743 | 923 | 809 |
| Operating Profit | -423 | -547 | -589 | -788 | -638 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -421 | -548 | -610 | -831 | -804 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -421 | -548 | -611 | -832 | -807 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -421 | -548 | -611 | -832 | -807 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -421 | -548 | -611 | -832 | -807 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.98 | -12.3 | -13.6 | -15.8 | -12.8 |
| Dividends per Share |